NCT04362150 Long-term Impact of Infection With Novel Coronavirus (COVID-19)
| NCT ID | NCT04362150 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of California, San Francisco |
| Condition | COVID |
| Study Type | OBSERVATIONAL |
| Enrollment | 800 participants |
| Start Date | 2020-04-21 |
| Primary Completion | 2030-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 800 participants in total. It began in 2020-04-21 with a primary completion date of 2030-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
LIINC is a study of volunteers who were previously infected with SARS-CoV-2 (also known as novel coronavirus or COVID-19) who have recovered from acute infection. The study is designed to provide a specimen bank of samples with carefully characterized clinical data. LIINC specimens will be used to examine multiple questions involving the virologic, immunologic, and host factors involved in COVID-19, with a focus on understanding variability in the long-term immune response between individuals.
Eligibility Criteria
Inclusion Criteria: 1. Willing and able to provide written informed consent, and 2. Age \>/= 18 years, and 3. A history of SARS-CoV-2 infection, as evidenced by: 1. Available laboratory documentation of SARS-CoV-2 RNA positivity on a nucleic acid amplification test or by serologic testing when this becomes available, or 2. Reference by the participant to a laboratory test performed on respiratory tract secretions or blood, fingerstick, or saliva test that was reported to the participant to be positive for SARS-CoV-2 or COVID-19 infection, 4. And a period of 21 days or more has elapsed since the first positive test or symptoms preceding the first positive test, whichever is earlier. Exclusion Criteria: 1. Self-reported or documented chronic anemia with hemoglobin \< 9 g/dL. Anemia during a preceding acute illness will not be exclusionary. 2. Serious medical or psychiatric illness that, in the opinion of the site investigator, would interfere with the ability to adhere to study requirements or to give informed consent. 3. Active drug or alcohol use or dependence that, in the opinion of the Principal Investigator, would interfere with adherence to study requirements or to give informed consent.
Contact & Investigator
Steven Deeks, MD
PRINCIPAL INVESTIGATOR
University of California, San Francisco
Frequently Asked Questions
Who can join the NCT04362150 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying COVID. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04362150 currently recruiting?
Yes, NCT04362150 is actively recruiting participants. Contact the research team at rebecca.hoh@ucsf.edu for enrollment information.
Where is the NCT04362150 trial being conducted?
This trial is being conducted at San Francisco, United States.
Who is sponsoring the NCT04362150 clinical trial?
NCT04362150 is sponsored by University of California, San Francisco. The principal investigator is Steven Deeks, MD at University of California, San Francisco. The trial plans to enroll 800 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.